Prot# 26593: A Phase II, Multi-Center, Randomized, Double-Blind, Placebo Controlled, Safety, Tolerability and Efficacy Study on Add-on Cladribine Tablet Therapy with Rebif New Formulation in Multiple Sclerosis Subjects with Active Disease

Project: Research project

Project Details

StatusFinished
Effective start/end date1/17/071/17/10

Funding

  • EMD Serono, Inc. (26593)